Literature DB >> 10543468

Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.

J D Luketich1, D M Friedman, T L Weigel, M A Meehan, R J Keenan, D W Townsend, C C Meltzer.   

Abstract

BACKGROUND: Pilot studies suggest positron emission tomography (PET) scanning may be superior to conventional imaging in staging esophageal cancer, especially in the detection of radiographically occult distant metastases. This report summarizes our experience with PET in staging esophageal cancer.
METHODS: One hundred consecutive PET scans in 91 patients with esophageal cancer referred for surgery were prospectively collected (1995 to 1998) and compared with computerized tomography (CT) and bone scan. PET images were acquired after injection of 18F-fluorodeoxyglucose and evaluated for abnormal uptake. Minimally invasive surgical staging (MIS) and/or clinical correlation were used to confirm or refute imaging results.
RESULTS: MIS or clinical correlation confirmed 70 distant metastases in 39 cases. PET detected 51 metastases in 27 of 39 cases (69% sensitivity, 93.4% specificity, 84% accuracy) compared with CT, which detected 26 metastases in 18 of 39 cases (46.1% sensitivity, 73.8% specificity, 63% accuracy) (p < 0.01).
CONCLUSIONS: PET was more accurate than CT in detecting distant metastases, but was only 69% sensitive compared with minimally invasive staging.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543468     DOI: 10.1016/s0003-4975(99)00974-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  59 in total

1.  Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.

Authors:  Jan-Christopher Metzger; Daniel Wollschläger; Matthias Miederer; Peter Vaupel; Markus Moehler; Heinz Schmidberger; Arnulf Mayer
Journal:  Strahlenther Onkol       Date:  2017-08-02       Impact factor: 3.621

2.  Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases.

Authors:  Yuanli Dong; Hui Guan; Wei Huang; Zicheng Zhang; Dongbo Zhao; Yang Liu; Tao Zhou; Baosheng Li
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

3.  Surgical management of esophageal carcinoma.

Authors:  Amit N Patel; John T Preskitt; Joseph A Kuhn; Robert F Hebeler; Richard E Wood; Harold C Urschel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

4.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 5.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 6.  The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.

Authors:  Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

Review 7.  Surgical treatment of superficial esophageal cancer.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Muneaki Shibakita; Yasuhito Tonomoto; Shinji Hattori; Ryoji Hyakudomi; Hiroshi Yoshimura; Dipok Kumar Dhar; Naofumi Nagasue
Journal:  Langenbecks Arch Surg       Date:  2006-07-08       Impact factor: 3.445

8.  Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.

Authors:  Cuong P Duong; Helen Demitriou; Leann Weih; Anne Thompson; David Williams; Robert J S Thomas; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-10       Impact factor: 9.236

Review 9.  Surgical management of esophageal malignancy.

Authors:  Dennis Blom
Journal:  Curr Gastroenterol Rep       Date:  2003-06

10.  The early use of PET-CT alters the management of patients with esophageal cancer.

Authors:  R N Williams; S S Ubhi; C D Sutton; A L Thomas; J J Entwisle; D J Bowrey
Journal:  J Gastrointest Surg       Date:  2009-01-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.